Teva/Ivax acquisition closes
Executive Summary
Teva completes $7.4 bil. acquisition of Ivax Jan. 26. The deal, announced in July 2005, makes Teva the world's largest generic pharmaceutical firm (1"The Pink Sheet" Aug. 1, 2005, p. 19). Teva said it "expects the acquisition to become accretive by the end of the first year." As part of FTC-ordered divestitures, to be completed by Feb. 5, Teva will sell 11 products to Par and four to Barr; all 15 products will be supplied by Teva until the companies can manufacturer the products independently...
You may also be interested in...
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.